What Is Homocysteine? Normal vs Optimal Range Explained

Labs flag homocysteine as abnormal only above 15 µmol/L, but this threshold was set to detect severe hyperhomocysteinemia—not the gradual vascular and neurological damage that begins at much lower levels. The CTD maps over 480 compounds that interact with homocysteine metabolism, including multiple medication classes that impair the B-vitamin-dependent clearance pathways. Cardiovascular risk increases linearly above 8 µmol/L with no safe threshold identified in large meta-analyses. A person walking around at 12 µmol/L—well within the lab-normal range—is experiencing chronic endothelial damage, increased platelet aggregation, and impaired nitric oxide production with every heartbeat. The optimal range of 5–8 µmol/L reflects a methylation cycle operating with adequate B12, folate, and B6 cofactors, where homocysteine is being efficiently recycled to methionine or converted to cysteine without accumulation.

Homocysteine sits at the intersection of two critical clearance pathways. The remethylation pathway uses B12 as a cofactor and methylfolate as a methyl donor to convert homocysteine back to methionine—the building block for SAMe, the body's universal methyl donor for DNA, neurotransmitters, and hundreds of other reactions. PubMed indexes over 38,000 publications on homocysteine, with cross-sectional analyses demonstrating that approximately 40 percent of the population carries MTHFR gene variants (C677T or A1298C) that reduce the enzyme's ability to produce methylfolate by 30–70 percent. These individuals have a genetic bottleneck in homocysteine clearance that makes them particularly sensitive to folate depletion from medications, poor diet, or supplementation with synthetic folic acid instead of the bioavailable L-methylfolate form that bypasses the impaired enzyme.

The transsulfuration pathway provides a secondary clearance route, using vitamin B6 as a cofactor to irreversibly convert homocysteine to cysteine and then glutathione—the body's primary intracellular antioxidant. FAERS data document elevated homocysteine or B-vitamin depletion as adverse events across over 120 medication entries, spanning metformin, proton pump inhibitors, anticonvulsants, and oral contraceptives. When both clearance pathways are compromised simultaneously—for example, a woman on oral contraceptives (depleting folate and B6) who also carries an MTHFR variant—homocysteine can climb rapidly into the 15–25 µmol/L range even in young, otherwise healthy individuals. The clinical power of homocysteine testing lies in its ability to reveal methylation dysfunction that affects not just cardiovascular risk but also mood, cognition, detoxification capacity, and pregnancy outcomes in a single affordable blood test.

“Comparative analysis of folate forms demonstrates that L-methylfolate achieves superior homocysteine reduction compared to synthetic folic acid, particularly in individuals carrying MTHFR polymorphisms that impair folate bioactivation.”

— Skavinska et al., Nutrition Reviews (2025)